[
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01320592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_PHOSPHORYLATION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":"The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression.",
        "rs value":null,
        "pmid":"PubMed:25002028",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03130439",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Olaparib",
        "Description":"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.",
        "rs value":null,
        "pmid":"PubMed:21862407",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01630226",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02000622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01945775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02032823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01145430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02561832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03329937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01351909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01104259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01251874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05519670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TSL-1502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05420779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lurbinectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02454972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Epirubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01074970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Trabectedin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00580112",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab + Olaparib + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mercaptopurine + Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01432145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04664972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03805399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04556292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aromatase inhibitors + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04240106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prophylactic contralateral breast irradiation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04960839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03575065",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Sapacitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03641755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05629429",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05209529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03990896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02826512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01009788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02595905",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02505048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04755868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02282345",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02681562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01661868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02849496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03286842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04296370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03150576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04915755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01905592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Fulvestrant + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04053322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Paclitaxel + Veliparib + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02032277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02163694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Choriogonadotropin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03495609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD9574",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05417594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":"c.2606T>G",
        "AA Mutation":"p.L869R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31867841",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).",
        "rs value":null,
        "pmid":"PubMed:17936563",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Lapatinib,Capecitabine",
        "Description":"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination chemotherapy (n=39) were associated with lower median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=87; PFS: 4.3 vs. 6.4 months, ORR: 17.1% vs 39.7%, OS 17.3 vs 27.8 mo).",
        "rs value":null,
        "pmid":"PubMed:26920887",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 2.50, P = 0.003, multivariate analysis) compared to wildtype PIK3CA.",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In retrospective study of 175 metastatic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 1.86, P = 0.014, multivariate analysis ) compared to wildtype PIK3CA.",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02038010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified_or_PTEN_unspecified_or_TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Nab-paclitaxel + Trastuzumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03273595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pilaralisib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01042925",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pilaralisib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01042925",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00829166",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified)_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03386162",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Elacestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05563220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel + Tilarginine acetate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05660083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03207529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01248494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Evexomostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05455619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01923168",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E545",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib,Fulvestrant",
        "Description":"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant across prespecified subgroups, including E542K, E545X (N=105, HR 0.61, 95% CI 0.37-1), and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Canagliflozin + Serabelisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04073680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02379247",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E542K",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Eribulin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04345913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))_and_(PIK3CA_D1045N_or_PIK3CA_D1056N_or_PIK3CA_E103_G106delinsD_or_PIK3CA_E103_V105del_or_PIK3CA_E110del_or_PIK3CA_E365K_or_PIK3CA_E39K_or_PIK3CA_E418K_or_PIK3CA_E418K_or_PIK3CA_E453_L455del_or_PIK3CA_E453K_or_PIK3CA_E453Q_or_PIK3CA_E542Q_or_PIK3CA_E726K_or_PIK3CA_G1049R_or_PIK3CA_G106_E109del_or_PIK3CA_G106_R108del_or_PIK3CA_G106C_or_PIK3CA_G106V_or_PIK3CA_G106V_or_PIK3CA_G118D_or_PIK3CA_H1047I_or_PIK3CA_H450_P458del_or_PIK3CA_L452_G460del_or_PIK3CA_L455_G460delinsC_or_PIK3CA_M1004I_or_PIK3CA_M1043I_or_PIK3CA_M1043V_or_PIK3CA_N1044K_or_PIK3CA_N345K_or_PIK3CA_N345S_or_PIK3CA_P104_V105delinsL_or_PIK3CA_P539R_or_PIK3CA_Q546K_or_PIK3CA_Q546P_or_PIK3CA_Q75E_or_PIK3CA_R108H_or_PIK3CA_R38C_or_PIK3CA_R88Q_or_PIK3CA_R93W_or_PIK3CA_V105_G106del_or_PIK3CA_V105del_or_PIK3CA_Y1021H)",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Dapagliflozin + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05025735",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047X",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status.PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant in across prespecified subgroups, including  E542K, E545X, and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02412722",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03206203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dactolisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01248494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Inavolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02423603",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01923168",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Ganitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01708161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. In the cohort of patients with PIK3CA-mutated cancer (defined by the presence of any PIK3CA mutation in mutation hot spots in the C2, helical, and kinase domains of PI3K corresponding to exons 7, 9, and 20, respectively), PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, 95% CI, 0.50 to 0.85, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85 (95% CI, 0.58 to 1.25). Overall response rate was also greater in the PIK3CA-mutant group (26.6% vs. 12.8%).",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",
        "rs value":null,
        "pmid":"PubMed:27091708",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01740336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Inavolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05646862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01319539",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01572727",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00894504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03803761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Everolimus",
        "Description":"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",
        "rs value":null,
        "pmid":"PubMed:27445490",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and\/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.",
        "rs value":null,
        "pmid":"PubMed:22842582",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IGF1R",
        "Genomic Position":"15:99192200-99507759(+) | 15q26.3",
        "CDS Mutation":null,
        "AA Mutation":"IGF1R_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Exemestane,Metformin",
        "Description":"A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IHC was performed and patients classified as IGF1R high (n=105) or low (n=50). In IGF1R-high patients, combining metformin with exemestane was associated with significant RFS (HR 1.12, 95% CI 0.57\ufffd\ufffd\ufffd2.23 for sequential treatment with metformin, HR 0.73 95% CI 0.56\ufffd\ufffd\ufffd0.94 for exemestane only, and HR 0.32, 95% CI 0.10\ufffd\ufffd\ufffd1.00 for exemestane with metformin, p = 0.02, compared to the sequential treatment arm). There was also significant association with OS (HR for OS 1.72, 95% CI 0.96\ufffd\ufffd\ufffd3.08 for sequential treatment with metformin, HR 0.80, 95% CI 0.62\ufffd\ufffd\ufffd1.03 for exemestane only, and HR 0.67, 95% CI 0.31\ufffd\ufffd\ufffd1.45 for exemestane with metformin, p = 0.03, compared to the sequential treatment arm). The authors conclude that adding metformin to exemestane for patients with IGF1R-high e",
        "rs value":null,
        "pmid":"PubMed:26706833",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R249",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin",
        "Description":"Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.",
        "rs value":null,
        "pmid":"PubMed:9569050",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_DNA_Binding_Domain_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen.",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05622058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02965950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00044993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Olaparib + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02624973",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":"c.1731C>A",
        "AA Mutation":"p.N577K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27551012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24055055",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1138G>C",
        "AA Mutation":"p.E380Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607T>A",
        "AA Mutation":"p.L536H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.L536",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24217577",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607",
        "AA Mutation":"p.L536Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.",
        "rs value":null,
        "pmid":"PubMed:24387334",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured from initiation of trastuzumab (HR = 1.92, P = 0.017) and diagnosis of first metastasis (HR = 1.69, P = 0.047).",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).",
        "rs value":null,
        "pmid":"PubMed:20813970",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Expression",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":"Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3\/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).",
        "rs value":null,
        "pmid":"PubMed:16404430",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death measured from initiation of trastuzumab (HR = 1.64, P = 0.029) and diagnosis of first metastasis (HR = 1.85, P = 0.003).",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Trastuzumab + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03273595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Eribulin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04345913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Copanlisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03939897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",
        "rs value":null,
        "pmid":"PubMed:27091708",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Expression",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Everolimus,Fulvestrant",
        "Description":"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",
        "rs value":null,
        "pmid":"PubMed:27445490",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1125976",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01915576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04768426",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01277757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.",
        "rs value":null,
        "pmid":"PubMed:26351323",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Cisplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion_and_PDCD4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemrametostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04676516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_Loss",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole,Palbociclib",
        "Description":"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.",
        "rs value":null,
        "pmid":"PubMed:26715889",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP2R2A",
        "Genomic Position":"8:26150732-26228402(+) | 8p21.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP2R2A_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04610528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04965766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00111787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib + Paclitaxel + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01688609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02226757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin-loaded anti-EGFR immunoliposomes",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02833766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00894504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Poziotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02544997",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Canertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00051051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03080805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_or_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00146172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03900884",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02034981",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F2108L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Rapamycin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27279227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03125928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04789096",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03726879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03820141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03894007",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04740918",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04759248",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02129556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02838823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04448886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride liposome + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03409198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Exemestane + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03841747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05093387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03164993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02513472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03012230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02555657",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02447003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Radiotherapy + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04690855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02755272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04770272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Carboplatin + Nab-paclitaxel + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04722718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelareorep + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04445844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03036488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02819518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05382286",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05475678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02685059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04739670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05112536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Oleclumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03616886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel + Tocilizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02981303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03812549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05068141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04913571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Nab-paclitaxel + Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05174832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05266937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Anthracycline + Nab-paclitaxel + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04914390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02411656",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03281954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + PVX-410 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04634747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02628132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05233696",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03197935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04799249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03371017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04085276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04148911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02425891",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01934335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01524978",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03794297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX208",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05092815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02281760",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":null,
        "AA Mutation":"NF1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAS0612",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":null,
        "AA Mutation":"NF1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinib + SHR7390",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pelareorep",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT01656538",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03344965",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02401347",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05232006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04756765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    }
]